These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 28884840)

  • 1. Hydroxycarbamide in children with sickle cell anaemia after first-dose vs. chronic therapy: pharmacokinetics and predictive models for drug exposure.
    Estepp JH; Wiczling P; Moen J; Kang G; Mack JM; Liem R; Panepinto JA; Garg U; Kearns G; Neville KA
    Br J Clin Pharmacol; 2018 Jul; 84(7):1478-1485. PubMed ID: 28884840
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of a pharmacokinetic-guided dose individualization strategy for hydroxyurea treatment in children with sickle cell anaemia.
    Dong M; McGann PT; Mizuno T; Ware RE; Vinks AA
    Br J Clin Pharmacol; 2016 Apr; 81(4):742-52. PubMed ID: 26615061
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early initiation of hydroxyurea (hydroxycarbamide) using individualised, pharmacokinetics-guided dosing can produce sustained and nearly pancellular expression of fetal haemoglobin in children with sickle cell anaemia.
    Quinn CT; Niss O; Dong M; Pfeiffer A; Korpik J; Reynaud M; Bonar H; Kalfa TA; Smart LR; Malik P; Ware RE; Vinks AA; McGann PT
    Br J Haematol; 2021 Aug; 194(3):617-625. PubMed ID: 34227124
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Robust clinical and laboratory response to hydroxyurea using pharmacokinetically guided dosing for young children with sickle cell anemia.
    McGann PT; Niss O; Dong M; Marahatta A; Howard TA; Mizuno T; Lane A; Kalfa TA; Malik P; Quinn CT; Ware RE; Vinks AA
    Am J Hematol; 2019 Aug; 94(8):871-879. PubMed ID: 31106898
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Population pharmacokinetics of hydroxyurea for children and adolescents with sickle cell disease.
    Wiczling P; Liem RI; Panepinto JA; Garg U; Abdel-Rahman SM; Kearns GL; Neville KA
    J Clin Pharmacol; 2014 Sep; 54(9):1016-22. PubMed ID: 24729271
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rationale, Development, and Validation of HdxSim, a Clinical Decision Support Tool for Model-Informed Precision Dosing of Hydroxyurea for Children with Sickle Cell Anemia.
    Power-Hays A; Dong M; Punt N; Mizuno T; Smart LR; Vinks AA; Ware RE
    Clin Pharmacol Ther; 2024 Sep; 116(3):670-677. PubMed ID: 38018175
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics and bioequivalence of a liquid formulation of hydroxyurea in children with sickle cell anemia.
    Estepp JH; Melloni C; Thornburg CD; Wiczling P; Rogers Z; Rothman JA; Green NS; Liem R; Brandow AM; Crary SE; Howard TH; Morris MH; Lewandowski A; Garg U; Jusko WJ; Neville KA;
    J Clin Pharmacol; 2016 Mar; 56(3):298-306. PubMed ID: 26201504
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low-dose hydroxycarbamide therapy may offer similar benefit as maximum tolerated dose for children and young adults with sickle cell disease in low-middle-income settings.
    Inusa BPD; Wale A; Hassan AA; Idhate T; Dogara L; Ijei I; Qin Y; Anie K; Lawson JO; Hsu L
    F1000Res; 2018; 7():. PubMed ID: 30228870
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chromosome damage and repair in children with sickle cell anaemia and long-term hydroxycarbamide exposure.
    McGann PT; Howard TA; Flanagan JM; Lahti JM; Ware RE
    Br J Haematol; 2011 Jul; 154(1):134-40. PubMed ID: 21542824
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hydroxyurea dose optimisation for children with sickle cell anaemia in sub-Saharan Africa (REACH): extended follow-up of a multicentre, open-label, phase 1/2 trial.
    Aygun B; Lane A; Smart LR; Santos B; Tshilolo L; Williams TN; Olupot-Olupot P; Stuber SE; Tomlinson G; Latham T; Ware RE;
    Lancet Haematol; 2024 Jun; 11(6):e425-e435. PubMed ID: 38701812
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hydroxycarbamide adherence and cumulative dose associated with hospital readmission in sickle cell disease: a 6-year population-based cohort study.
    Zhou J; Han J; Nutescu EA; Gordeuk VR; Saraf SL; Calip GS
    Br J Haematol; 2018 Jul; 182(2):259-270. PubMed ID: 29767446
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG).
    Wang WC; Ware RE; Miller ST; Iyer RV; Casella JF; Minniti CP; Rana S; Thornburg CD; Rogers ZR; Kalpatthi RV; Barredo JC; Brown RC; Sarnaik SA; Howard TH; Wynn LW; Kutlar A; Armstrong FD; Files BA; Goldsmith JC; Waclawiw MA; Huang X; Thompson BW;
    Lancet; 2011 May; 377(9778):1663-72. PubMed ID: 21571150
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of hydroxcarbamide therapy on survival of children with sickle cell disease.
    Lobo CL; Pinto JF; Nascimento EM; Moura PG; Cardoso GP; Hankins JS
    Br J Haematol; 2013 Jun; 161(6):852-60. PubMed ID: 23590693
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hydroxyurea Optimization through Precision Study (HOPS): study protocol for a randomized, multicenter trial in children with sickle cell anemia.
    Meier ER; Creary SE; Heeney MM; Dong M; Appiah-Kubi AO; Nelson SC; Niss O; Piccone C; Quarmyne MO; Quinn CT; Saving KL; Scott JP; Talati R; Latham TS; Pfeiffer A; Shook LM; Vinks AA; Lane A; McGann PT
    Trials; 2020 Nov; 21(1):983. PubMed ID: 33246482
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I study of magnesium pidolate in combination with hydroxycarbamide for children with sickle cell anaemia.
    Hankins JS; Wynn LW; Brugnara C; Hillery CA; Li CS; Wang WC
    Br J Haematol; 2008 Jan; 140(1):80-5. PubMed ID: 17991298
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hydroxycarbamide alters erythroid gene expression in children with sickle cell anaemia.
    Flanagan JM; Steward S; Howard TA; Mortier NA; Kimble AC; Aygun B; Hankins JS; Neale GA; Ware RE
    Br J Haematol; 2012 Apr; 157(2):240-8. PubMed ID: 22360576
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Opportunities for model-based precision dosing in the treatment of sickle cell anemia.
    Dong M; Mizuno T; Vinks AA
    Blood Cells Mol Dis; 2017 Sep; 67():143-147. PubMed ID: 28807656
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hydroxyurea Pharmacokinetics in Pediatric Patients After Total Pancreatectomy With Islet Autotransplantation.
    Boucher AA; Dong M; Vinks AA; Marahatta A; Howard TA; Ware RE; Nathan JD; Abu-El-Haija M; Luchtman-Jones L
    J Clin Pharmacol; 2021 Apr; 61(4):547-554. PubMed ID: 33029796
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hydroxyurea: Analytical techniques and quantitative analysis.
    Marahatta A; Ware RE
    Blood Cells Mol Dis; 2017 Sep; 67():135-142. PubMed ID: 28847416
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oscillatory haematopoiesis in adults with sickle cell disease treated with hydroxycarbamide.
    Baird JH; Minniti CP; Lee JM; Tian X; Wu C; Jackson M; Alam S; Taylor JG; Kato GJ
    Br J Haematol; 2015 Mar; 168(5):737-46. PubMed ID: 25377027
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.